Multigene and Biomarker Testing in Breast Cancer: What is the Role?
Biomarkers identify patients who are likely to respond to a given therapy. Clinical oncologists and pathologists would benefit greatly from understanding the technology involved in molecular testing and profiling assays and their interpretation. Clinicians need to know what, when, and how to test and how to make subsequent informed, patient‐personalized treatment decisions. Accurate interpretation of results is critical; over-interpretation or misinterpretation will lead to treatment of patients with ineffective and expensive therapies, negatively impacting patient outcomes.
This educational program is designed to meet the educational needs of physicians, nurse practitioners, nurses, PAs, pharmacists, and other health care professionals who manage patients with breast cancer.
Following this program, participants should be able to:
- Identify the biomarker tests that are recommended for early stage versus metastatic breast cancer and their roles.
- Compare and contrast the various techniques/assays available for biomarker testing.
- Incorporate biomarker testing and test results into clinical practice for the management of patients with breast cancer.
Harold J. Burstein, MD, PhD
Dana-Farber/Brigham and Women’s Cancer Center |
Massachusetts General Hospital Cancer Center
Anthony D. Elias, MD
University of Colorado Cancer Center
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
The faculty listed below have no relevant financial relationship(s) with ineligible companies to disclose.
Harold J. Burstein, MD, PhD
The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Anthony D. Elias, MD
Astellas Pharma US, Inc.: Grant/Research Support
BioAtla Inc.: Grant/Research Support
C4 Therapeutics, Inc.: Grant/Research Support
Epizyme: Grant/Research Support
Fosun Orinove Pharma Tech, Inc: Grant/Research Support
ImmuneOnco Biopharmaceuticals Co., Ltd: Grant/Research Support
Infinity Pharmaceuticals, Inc.: Grant/Research Support
PTC Therapeutics: Grant/Research Support
Quantum Leap Health Consortium: Grant/Research Support
Zenshine Pharmaceuticals: Grant/Research Support
Planning Committee and NCCN Staff Disclosures
The planner listed below has the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for this individual have been mitigated.
William J. Gradishar, MD
AstraZeneca Pharmaceuticals LP: Honoraria; Scientific Advisor
Biotheronostics: Honoraria; Scientific Advisor
Daiichi-Sankyo co.: Honoraria; Scientific Advisor
Eli Lilly and Company: Scientific Advisor
ImmunoGen, Inc.: Honoraria; Scientific Advisor
MacroGenics: Scientific Advisor
Puma Biotechnology: Scientific Advisor
Seattle Genetics, Inc.: Scientific Advisor
None of the other planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 1.25 contact hours.
NCCN designates this knowledge-based continuing education activity for 1.25 contact hours (0.125 CEUs) of continuing education credit. UAN: JA4008196-0000-23-023-H01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. Approval is valid until March 15, 2024. PAs should only claim credit commensurate with the extent of their participation.
- 1.25 AAPA Category 1 CME credit
- 1.25 ACPE contact hours
- 1.25 AMA PRA Category 1 Credit™
- 1.25 ANCC contact hours
- 1.25 Participation
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing